title: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
authors.affiliation: Medical Practices Evaluation Center, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Barry
authors.forename: C
authors.initials: C
authors.lastname: Fleming
authors.forename: C M
authors.initials: CM
authors.lastname: Coley
authors.forename: J H
authors.initials: JH
authors.lastname: Wasson
authors.forename: M C
authors.initials: MC
authors.lastname: Fahs
authors.forename: J E
authors.initials: JE
authors.lastname: Oesterling
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D003452:Cryosurgery; D005500:Follow-Up Studies; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000331:legislation & jurisprudence*; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000331:legislation & jurisprudence; D006278:Medicare / Q000331:legislation & jurisprudence*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000191:economics / Q000628:therapy*; D011878:Radiotherapy; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D017430:Prostate-Specific Antigen